Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Vanda Pharmaceuticals, Inc.
Glancy Binkow & Goldberg LLP Announces Class Action Lawsuit Against Vanda Pharmaceuticals, Inc. Business Wire LOS ANGELES -- June 27, 2013 Glancy Binkow & Goldberg LLP announces that a class action lawsuit has been filed in the United States District Court for the District of Columbia on behalf of a class (the “Class”) comprising all purchasers of the securities of Vanda Pharmaceuticals, Inc. (“Vanda” or the “Company”) (NASDAQ:VNDA) between December 18, 2012 and June 18, 2013, inclusive (the “Class Period”). A COPY OF THE COMPLAINT IS AVAILABLE FROM THE COURT OR FROM GLANCY BINKOW & GOLDBERG LLP. PLEASE CONTACT US TOLL-FREE AT (888) 773-9224, OR AT (212) 682-5340, OR BY EMAIL TO SHAREHOLDERS@GLANCYLAW.COM TO DISCUSS THIS MATTER. IF YOU INQUIRE BY EMAIL PLEASE INCLUDE YOUR MAILING ADDRESS, TELEPHONE NUMBER AND NUMBER OF SHARES PURCHASED. Vanda is a biopharmaceutical company engaged in the development and commercialization of products for the treatment of central nervous system disorders, including tasimelteon -- a treatment for circadian rhythm sleep disorders (CRSD) and currently in clinical development for a serious, rare CRSD known as “Non-24.” The Complaint alleges that during the Class Period the Company issued false and/or misleading statements and/or failed to disclose that: (a) the Company was forced to unilaterally change the primary endpoint in the middle of the tasimelteon Phase III studies as it was in possession of data suggesting the original primary endpoint would not be met; (b) the Company eliminated nighttime total sleep as the primary endpoint in its studies as there was no discernible difference in efficacy and safety in nighttime total sleep between those patients deemed to have Non-24 and those patients with a normal circadian rhythm; (c) the replacement primary endpoint installed to assess tasimelteon’s efficacy and safety was created by the Company based on predicted results and has never been used before in sleep-drug clinical trials, nor was it endorsed by the Food and Drug Administration; and (d) as a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times. If you are a member of the Class described above you may move the Court no later than 60 days from June 25, 2013 to serve as lead plaintiff; however, you must meet certain legal requirements. If you wish to learn more about this action or if you purchased Vanda securities prior to the Class Period and have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Michael Goldberg, Esquire, of Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite 2100, Los Angeles, California 90067, Toll Free at (888) 773-9224, or contact Gregory Linkh, Esquire, of Glancy Binkow & Goldberg LLP at 122 E. 42nd Street, Suite 2920, New York, New York 10168, at (212) 682-5340, by e-mail to firstname.lastname@example.org, or visit our website at http://www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contact: Glancy Binkow & Goldberg LLP, Los Angeles, CA Michael Goldberg (888) 773-9224 or Glancy Binkow & Goldberg LLP, New York, NY Gregory Linkh (212) 682-5340 or (888) 773-9224 email@example.com www.glancylaw.com